Published in Law and Health Weekly, January 14th, 2006
Evotec has granted Takeda exclusive rights in a novel target in Alzheimer disease based on successful target identification and validation work triggering a milestone payment of a few million Euro. Importantly, Evotec is eligible for further substantial milestone payments on the successful clinical development of compounds acting on the selected target. Further work within the collaboration is rapidly and productively progressing. Evotec is entitled to additional milestone payments should Takeda select additional targets...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.